Latest Breaking News On - Bicara therapeutics - Page 5 : comparemela.com

Bicara Therapeutics Presents New Data from Ongoing Phase 1/1b Trial of Lead First-in-Class Bifunctional Program, BCA101, at the European Society for Medical Oncology (ESMO) Congress 2022

Stage one efficacy threshold achieved in dose expansion in patients with squamous cell carcinoma of the head and neck Webinar to review data to be held Monday, September 12th at 10:30 a.m. ET, featuring

France generalKostenloser wertpapierhandelSarah mccabeChris raileyLiviu niculescuGlennj hannaStern investor relations incDana farber cancer instituteEuropean society for medical oncologyPrincipal investigator glennEuropean societyMedical oncologyRare headNeck cancersPrincipal investigatorChief medical officer

Bicara Therapeutics to Present Clinical Data from Lead Precision Tumor Modulator Program, BCA101, at ESMO Congress 2022

Bicara Therapeutics, a clinical-stage biotechnology company developing dual-action biologics designed to elicit a potent and durable immune response in the tumor microenvironment, today announced that

France generalKostenloser wertpapierhandelSarah mccabeChris raileyGlennj hannaStern investor relations incEuropean society for medical oncologyBicara therapeuticsEuropean societyMedical oncologyParis expo porte de versaillesMini oralInvestor relationsBridge communications

Bicara Therapeutics to Present Clinical Data from Lead Bifunctional Antibody Program, BCA101, at ASCO 2022 Annual Meeting

Bicara Therapeutics to Present Clinical Data from Lead Bifunctional Antibody Program, BCA101, at ASCO 2022 Annual Meeting
morningstar.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from morningstar.com Daily Mail and Mail on Sunday newspapers.

United statesSarah mccabePhilippel bedardChris raileyGlennj hannaBifunctional antibody programStern investor relations incAmerican society of clinical oncologyBicara therapeuticsPresent clinical dataLead bifunctional antibody programAmerican societyClinical oncologyPoster discussion sessionDevelopmental therapeuticsInvestor relations

Biocon slips after weak Q1 performance

Biocon slips after weak Q1 performance
business-standard.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from business-standard.com Daily Mail and Mail on Sunday newspapers.

United statesAndhra pradeshKiran mazumdar shawJohn shawBicara therapeutics incResearch servicesNovel biologicsBicara therapeuticsCapital marketஒன்றுபட்டது மாநிலங்களில்ஆந்திரா பிரதேஷ்கிறன் மஜும்தர் ஷாஜான் ஷாஆராய்ச்சி சேவைகள்நாவல் உயிரியல்மூலதனம் சந்தை

Biocon Q1 net profit declines 35% to Rs 108 4 cr; revenue at Rs 1807 8 cr

Biocon Q1 net profit declines 35% to Rs 108 4 cr; revenue at Rs 1807 8 cr
business-standard.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from business-standard.com Daily Mail and Mail on Sunday newspapers.

United statesAndhra pradeshKiran mazumdar shawJohn shawBicara therapeutics incResearch servicesBiocon ltdBicara therapeuticsExecutive chairperson kiran mazumdar shawNon executive directorAnnual general meetingBiocon executive chairperson kiranஒன்றுபட்டது மாநிலங்களில்ஆந்திரா பிரதேஷ்கிறன் மஜும்தர் ஷாஜான் ஷா